Supplementary Materials & Methods

Electrophysiology
Tissue cell culture and stable transfection: HEK293T cells stably transfected with hSCN1A, hSCN2A, hSCN3A, hSCN5A, hSCN9A and hSCN10A were maintained in Bonferroni correction was applied to take into account multiple comparisons in
Supplementary Figure S1 . and Multiclamp 700B amplifiers connected to a personal computer using Axon Digidata 1322A data acquisition hardware (Molecular Devices Inc., Sunnyvale, CA, USA). Series resistance compensation up to 80% was used to minimize voltage errors and achieve good voltage-clamp. Cells were observed with Nikon TE2000-U or Nikon TS-100 fluorescence microscopes using bandpass filters of 455-495 nm and 515-555 nm for excitation and emission, respectively. Cells displaying strong fluorescence were selected for current recording and >70% of these cells displayed co-transfected current. Pipettes were pulled from GC 150 F-15 borosilicate glass capillaries in five stages and firepolished, resulting in electrodes having 3-5 MΩ resistance in the bath.
For most channels, the bath solution consisted of (in mM) 145 NaCl, achieved using a gravity-flow perfusion system. Excess fluid was removed continuously.
Pulse protocols: For measurement of hK V 1.7 currents, 15-ms depolarizing pulses to +50 mV were applied from a holding potential of -100 mV, every 15 s. For measurement of hK V 10.1 currents, 3000-ms depolarizing pulses to +50 mV were applied from a holding potential of -60 mV, every 15 s. hK V 11.1 currents were evoked by a voltage step to +20 mV followed by a step to -40 mV during which peak current was measured. The holding potential was −80 mV, and pulses were delivered every 30 s. Ca 2+ -activated K + channels were studied using ramp protocols of 150 ms duration ranging from -120 mV to +50 mV every 15 s. The holding potential was -100 mV for K Ca 1.3 and K Ca 3.1, whereas the holding potential was -85 mV for K Ca 2.2 channels.
The pClamp10 software package (Molecular Devices, Sunnyvale, CA, USA) was used for data acquisition and analysis. Generally, currents were low-pass filtered using the built-in analog 4-pole Bessel filters of the amplifiers and sampled (2-50 kHz) at least twice the filter cut-off frequency. Before analysis, whole-cell current traces were corrected for ohmic leakage and digitally filtered (three-point boxcar smoothing). The fraction of control current was determined as I/I 0 , where I and I 0 are the peak currents in the presence and absence of 300 nM Hm1a, respectively. (hERG) currents in the absence (control) and presence of 300 nM Hm1a. Currents were evoked by a test potential to +20 mV followed by a step to -40 mV. (d) Whole-cell K Ca 1.1 currents were evoked by voltage ramps ranging from -120 mV to +50 mV in the absence (control) and presence of 300 nM Hm1a. TEA (25 mM) was used as a positive control. (e) Whole-cell K Ca 2.2 currents were evoked by voltage ramps ranging from -120 mV to +50 mV in the absence (control) and presence of 300 nM Hm1a. 1 nM apamin solution was used as a positive control. (f) Whole-cell K Ca 3.1 currents were evoked by voltage ramps ranging from -120 mV to +50 mV in the absence (control) and presence of 300 nM Hm1a. TEA (25 mM) was used as a positive control. Spectral plots were calculated from ECoG recordings for 0-10 Hz for 30-min epoch before peptide infusion compared to 30 min post-peptide infusion for Dravet syndrome mice (n = 9). AUC for each frequency band was compared using a paired t-test.
Movie S1. Dravet syndrome mice before ICV infusion of Hm1a. Example of four mice video monitored continuously prior to Hm1a delivery. Mouse #3 displays a spontaneous seizure, one of several events recorded before peptide was administered. The seizure begins suddenly with running/jumping, the animal shows movement recapitulating a tonic-clonic event, and then it remains motionless for several minutes (Movie 15 s duration).
